Prevalence and clinical association of sarcopenia among Thai patients with systemic sclerosis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 10 2022
28 10 2022
Historique:
received:
11
06
2021
accepted:
05
10
2022
pubmed:
29
10
2022
medline:
2
11
2022
entrez:
28
10
2022
Statut:
epublish
Résumé
Patients with systemic sclerosis (SSc) have some potential factors associated with an increased risk of sarcopenia. There has been currently no study to examine such associations in SSc patients. We aimed to determine the prevalence of sarcopenia among SSc patients and examine its association with clinical manifestations and laboratory tests. A cross-sectional study was conducted in 180 adult SSc patients at the Scleroderma Clinic, Khon Kaen University, Thailand, between July 2019 and April 2020. Clinical data, laboratory tests for inflammatory markers, serology, hormone, body composition by dual-energy X-ray absorptiometry, handgrip strength, functional lower extremity strength, and usual gait speed were collected and measured. Sarcopenia was defined according to the criteria of the Asian Working Group for Sarcopenia. One hundred and eighty patients were recruited. Ninety-four cases (52.2%) were the diffuse cutaneous SSc subset. The respective mean age and duration of disease was 58.8 ± 9.4 and 6.2 ± 5.3 years. Sarcopenia was revealed in 41 SSc patients for a prevalence of 22.8% (95% CI 12.1-34.8), while the prevalence was higher in patients with the diffuse cutaneous SSc (dcSSc) compared to the limited cutaneous SSc. BMI at the onset of SSc and C-reactive protein > 5 mg/dL were significantly associated with sarcopenia with a respective OR of 0.60 (95% CI 0.48-0.75) and 3.18 (1.06-9.54). Sarcopenia is common in patients with SSc, but the prevalence is more pronounced in the dcSSc. Inflammatory markers, particularly the CRP level, are strongly associated. BMI at the onset had a negative association with sarcopenia among SSc patients.
Identifiants
pubmed: 36307496
doi: 10.1038/s41598-022-21914-w
pii: 10.1038/s41598-022-21914-w
pmc: PMC9616808
doi:
Substances chimiques
Biomarkers
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18198Informations de copyright
© 2022. The Author(s).
Références
J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2
pubmed: 32033882
J Clin Endocrinol Metab. 2010 Jun;95(6):2630-3
pubmed: 20525913
Eur J Rheumatol. 2015 Dec;2(4):131-134
pubmed: 27708949
N Engl J Med. 2007 Jul 19;357(3):266-81
pubmed: 17634462
Arthritis Rheum. 2013 Nov;65(11):2737-47
pubmed: 24122180
Nutrition. 2018 Nov;55-56:51-55
pubmed: 29960157
PLoS One. 2013;8(3):e60119
pubmed: 23533671
Clin Rheumatol. 2011 Sep;30(9):1235-40
pubmed: 21484224
J Nutr Health Aging. 2020;24(1):83-90
pubmed: 31886813
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
Eur J Appl Physiol. 2010 Sep;110(1):57-65
pubmed: 20390291
J Rheumatol. 1988 Feb;15(2):202-5
pubmed: 3361530
Ann Rheum Dis. 2010 Oct;69(10):1809-15
pubmed: 20551155
J Cachexia Sarcopenia Muscle. 2013 Jun;4(2):137-44
pubmed: 23389764
Age (Dordr). 2014;36(4):9674
pubmed: 24994536
Clin Rheumatol. 2018 Apr;37(4):987-997
pubmed: 29196890
Am J Clin Pathol. 2020 Jan 1;153(1):14-29
pubmed: 31598629
Rheumatol Int. 2019 Oct;39(10):1767-1775
pubmed: 31372720
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545968
J Am Med Dir Assoc. 2014 Feb;15(2):95-101
pubmed: 24461239
Clin Rheumatol. 2013 Jul;32(7):1037-44
pubmed: 23549639
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):76-81
pubmed: 29998834
Geriatr Gerontol Int. 2012 Jul;12(3):388-96
pubmed: 22530761
Ann N Y Acad Sci. 2007 Jun;1108:268-82
pubmed: 17899625
J Diabetes Metab Disord. 2017 May 16;16:21
pubmed: 28523252
Curr Opin Rheumatol. 2014 Mar;26(2):124-30
pubmed: 24419752
Semin Hematol. 2015 Oct;52(4):261-9
pubmed: 26404438
Arch Public Health. 2014 Dec 18;72(1):45
pubmed: 25810912